Bonaca, Marc P.

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

Wiviott, S. D., Raz, I., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Silverman, M. G., Zelniker, T. A., Kuder, J. F., Murphy, S. A., et al. (2019) · New England Journal of Medicine

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 6,382

SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials

Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 2,845

Long-term use of ticagrelor in patients with prior myocardial infarction

Bonaca, M. P., Bhatt, D. L., Cohen, M., Steg, P. G., Storey, R. F., Jensen, E. C., Magnani, G., Bansilal, S., Fish, M. P., Im, K., et al. (2015) · New England Journal of Medicine

Antiplatelet Therapy and Cardiovascular DiseasesAcute Myocardial Infarction Research

Cited by 1,999

Cardiovascular toxicities associated with immune checkpoint inhibitors: an observational, retrospective, pharmacovigilance study

Salem, J.-E., Manouchehri, A., Moey, M., Lebrun-Vignes, B., Bastarache, L., Pariente, A., Gobert, A., Spano, J.-P., Balko, J. M., Bonaca, M. P., et al. (2018) · The Lancet Oncology

Cancer Immunotherapy and BiomarkersPharmacovigilance and Adverse Drug Reactions

Cited by 1,271

Rivaroxaban in Peripheral Artery Disease after Revascularization

Bonaca, M. P., Bauersachs, R. M., Anand, S. S., Debus, E. S., Nehler, M. R., Patel, M. R., Fanelli, F., Capell, W. H., Diao, L., Jaeger, N., et al. (2020) · New England Journal of Medicine

Peripheral Artery Disease ManagementAntiplatelet Therapy and Cardiovascular Diseases

Cited by 1,045

Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus: Systematic Review and Meta-Analysis of Cardiovascular Outcomes Trials

Zelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Furtado, R. H. M., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., et al. (2019) · Circulation

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 781

Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk)

Bonaca, M. P., Nault, P., Giugliano, R. P., Keech, A. C., Pineda, A. L., Kanevsky, E., Kuder, J., Murphy, S. A., Jukema, J. W., Lewis, B. S., et al. (2018) · Circulation

Lipoproteins and Cardiovascular HealthPeripheral Artery Disease Management

Cited by 766

Effect of dapagliflozin on heart failure and mortality in type 2 diabetes mellitus

Kato, E. T., Silverman, M. G., Mosenzon, O., Zelniker, T. A., Cahn, A., Furtado, R. H. M., Kuder, J., Murphy, S. A., Bhatt, D. L., Leiter, L. A., et al. (2019) · Circulation

Diabetes Treatment and ManagementHeart Failure Treatment and Management

Cited by 557

Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial

Zelniker, T. A., Bonaca, M. P., Furtado, R. H. M., Mosenzon, O., Kuder, J. F., Murphy, S. A., Bhatt, D. L., Leiter, L. A., McGuire, D. K., Wilding, J. P. H., et al. (2020) · Circulation

Diabetes Treatment and ManagementAtrial Fibrillation Management and Outcomes

Cited by 459

Effect of Darapladib on Major Coronary Events After an Acute Coronary Syndrome: The SOLID-TIMI 52 Randomized Clinical Trial

O’Donoghue, M. L., Braunwald, E., White, H. D., Steen, D. P., Lukas, M. A., Tarka, E., Steg, P. G., Hochman, J. S., Bode, C., Maggioni, A. P., et al. (2014) · JAMA

Lipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular Diseases

Cited by 456

Cardiovascular Safety of Lorcaserin in Overweight or Obese Patients

Bohula, E. A., Wiviott, S. D., McGuire, D. K., Inzucchi, S. E., Kuder, J., Im, K., Fanola, C. L., Qamar, A., Brown, C., Budaj, A., et al. (2018) · New England Journal of Medicine

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 265

Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial

O’Donoghue, M. L., Glaser, R., Cavender, M. A., Aylward, P. E., Bonaca, M. P., Budaj, A., Davies, R. Y., Dellborg, M., Fox, K. A. A., Gutierrez, J. A. T., et al. (2016) · JAMA

Acute Myocardial Infarction ResearchCardiac Fibrosis and Remodeling

Cited by 249

Reduction in ischemic events with ticagrelor in diabetic patients with prior myocardial infarction in PEGASUS–TIMI 54

Bhatt, D. L., Bonaca, M. P., Bansilal, S., Angiolillo, D. J., Cohen, M., Storey, R. F., Im, K., Murphy, S. A., Held, P., Braunwald, E., et al. (2016) · Journal of the American College of Cardiology

Antiplatelet Therapy and Cardiovascular DiseasesAcute Myocardial Infarction Research

Cited by 216

Microvascular disease, peripheral artery disease, and amputation

Beckman, J. A., Duncan, M. S., Damrauer, S. M., Wells, Q. S., Barnett, J. V., Wasserman, D. H., Bedimo, R. J., Butt, A. A., Marconi, V. C., Sico, J. J., et al. (2019) · Circulation

Peripheral Artery Disease ManagementDiabetic Foot Ulcer Assessment and Management

Cited by 196

Semaglutide and walking capacity in people with symptomatic peripheral artery disease and type 2 diabetes (STRIDE): a phase 3b, double-blind, randomised, placebo-controlled trial

Bonaca, M. P., Catarig, A.-M., Houlind, K., Ludvik, B., Nordanstig, J., Ramesh, C. K., Rasouli, N., Sourij, H., Videmark, A., & Verma, S. (2025) · The Lancet

Peripheral Artery Disease ManagementDiabetes Treatment and Management

Cited by 176

Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study

McClung, M. R., O'Donoghue, M. L., Papapoulos, S. E., Bone, H., Langdahl, B., Saag, K. G., Reid, I. R., Kiel, D. P., Cavallari, I., Bonaca, M. P., et al. (2019) · The Lancet Diabetes & Endocrinology

Bone health and osteoporosis researchMenopause: Health Impacts and Treatments

Cited by 169

Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction

Bohula, E. A., Bonaca, M. P., Braunwald, E., Aylward, P. E., Corbalan, R., De Ferrari, G. M., He, P., Lewis, B. S., Merlini, P. A., Murphy, S. A., et al. (2016) · Circulation

Antiplatelet Therapy and Cardiovascular DiseasesAcute Myocardial Infarction Research

Cited by 168

Polyvascular disease, type 2 diabetes, and long-term vascular risk: a secondary analysis of the IMPROVE-IT trial

Bonaca, M. P., Gutierrez, J. A., Cannon, C., Giugliano, R., Blazing, M., Park, J.-G., White, J., Tershakovec, A., & Braunwald, E. (2018) · The Lancet Diabetes & Endocrinology

Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and Lipoproteins

Cited by 153

Effect of lorcaserin on prevention and remission of type 2 diabetes in overweight and obese patients (CAMELLIA-TIMI 61): a randomised, placebo-controlled trial

Bohula, E. A., Scirica, B. M., Inzucchi, S. E., McGuire, D. K., Keech, A. C., Smith, S. R., Kanevsky, E., Murphy, S. A., Leiter, L. A., Dwyer, J. P., et al. (2018) · The Lancet

Pharmacology and Obesity TreatmentDiabetes Treatment and Management

Cited by 94

Comparative Efficacy of Endovascular Revascularization Versus Supervised Exercise Training in Patients With Intermittent Claudication

Pandey, A., Banerjee, S., Ngo, C., Mody, P., Marso, S. P., Brilakis, E. S., Armstrong, E. J., Giri, J., Bonaca, M. P., Pradhan, A., et al. (2017) · JACC: Cardiovascular Interventions

Peripheral Artery Disease ManagementCardiovascular and exercise physiology

Cited by 89

Vorapaxar in Patients With Diabetes Mellitus and Previous Myocardial Infarction: Findings From the Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50 Trial

Cavender, M. A., Scirica, B. M., Bonaca, M. P., Angiolillo, D. J., Dalby, A. J., Dellborg, M., Morais, J., Murphy, S. A., Ophuis, T. O., Tendera, M., et al. (2015) · Circulation

Antiplatelet Therapy and Cardiovascular DiseasesAcute Myocardial Infarction Research

Cited by 80

Prospective Cardiovascular Surveillance of Immune Checkpoint Inhibitor–Based Combination Therapy in Patients With Advanced Renal Cell Cancer: Data From the Phase III JAVELIN Renal 101 Trial

Rini, B. I., Moslehi, J. J., Bonaca, M., Schmidinger, M., Albiges, L., Choueiri, T. K., Motzer, R. J., Atkins, M. B., Haanen, J., Mariani, M., et al. (2022) · Journal of Clinical Oncology

Renal cell carcinoma treatmentChemotherapy-induced cardiotoxicity and mitigation

Cited by 77

Supervised exercise therapy for symptomatic peripheral artery disease among medicare beneficiaries between 2017 and 2018: Participation rates and outcomes

Divakaran, S., Carroll, B. J., Chen, S., Shen, C., Bonaca, M. P., & Secemsky, E. A. (2021) · Circulation: Cardiovascular Quality and Outcomes

Peripheral Artery Disease ManagementCardiovascular and exercise physiology

Cited by 62

Cardiovascular efficacy of liraglutide and semaglutide in individuals with diabetes and peripheral artery disease

Verma, S., Al‐Omran, M., Leiter, L. A., Mazer, C. D., Rasmussen, S., Saevereid, H. A., Sejersten Ripa, M., & Bonaca, M. P. (2022) · Diabetes, Obesity and Metabolism

Diabetes Treatment and ManagementPeripheral Artery Disease Management

Cited by 61